DexCom, Inc. $DXCM Stake Increased by Nippon Life Global Investors Americas Inc.

Nippon Life Global Investors Americas Inc. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 53.9% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 82,170 shares of the medical device company’s stock after purchasing an additional 28,770 shares during the quarter. Nippon Life Global Investors Americas Inc.’s holdings in DexCom were worth $7,090,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of DXCM. Legal & General Group Plc bought a new stake in DexCom during the 2nd quarter valued at $173,237,000. Deutsche Bank AG purchased a new stake in shares of DexCom in the second quarter worth approximately $164,035,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of DexCom by 15.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company’s stock valued at $758,487,000 after purchasing an additional 1,515,702 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of DexCom in the second quarter valued at approximately $89,940,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of DexCom by 100.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,545,103 shares of the medical device company’s stock valued at $159,832,000 after purchasing an additional 1,275,142 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Sadie Stern sold 2,565 shares of the stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $88.37, for a total transaction of $226,669.05. Following the completion of the sale, the executive vice president directly owned 126,043 shares in the company, valued at approximately $11,138,419.91. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the sale, the executive vice president owned 98,185 shares in the company, valued at approximately $8,392,853.80. This represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 22,822 shares of company stock valued at $1,920,193. 0.28% of the stock is currently owned by insiders.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported revenue of approximately $1.34 billion, up 11.1% year over year, and adjusted earnings of $0.73 per share, surpassing analyst estimates of $0.68. U.S. revenue grew 14%, supported by demand for its continuous glucose monitoring products and adoption of the G7 15 Day system. DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
• Positive Sentiment: Margins improved materially. Non-GAAP operating margin reached 25.3%, while gross profit increased 18.2% and operating profit rose 34.9% year over year. The stronger earnings profile likely reinforced confidence in DexCom’s growth and cost management. DexCom Q3 2026 Earnings
• Positive Sentiment: Full-year outlook was raised. Management increased the midpoint of its 2026 revenue forecast to a range of $5.20 billion to $5.25 billion and lifted operating-margin and adjusted-EBITDA-margin guidance.
• Positive Sentiment: Shareholder returns received a boost. DexCom authorized a new $1.0 billion share buyback, which could support earnings per share and signal management’s confidence in cash generation. DexCom Announces $1 Billion Equity Buyback
• Positive Sentiment: Analyst sentiment improved. Barclays raised its price target from $115 to $120 while maintaining an “overweight” rating, citing potential upside following the results and improved outlook.
• Neutral Sentiment: Institutional ownership data showed substantial buying by several funds, including Invesco and Arrowstreet, but also significant reductions by other investors. This suggests mixed positioning rather than a clear institutional consensus.
• Negative Sentiment: Insider selling remains a cautionary signal. DexCom insiders reported 26 open-market sales and no purchases over the past six months. A recent sale by EVP Sadie Stern was made under a pre-arranged Rule 10b5-1 plan, reducing its predictive value, but the broader pattern may limit enthusiasm among some investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DXCM. Canaccord Genuity Group set a $90.00 target price on DexCom and gave the company a “buy” rating in a research report on Monday, August 3rd. Wells Fargo & Company raised their target price on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings upgraded DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 6th. Robert W. Baird set a $105.00 target price on shares of DexCom in a research report on Friday, July 31st. Finally, BTIG Research upped their price objective on shares of DexCom from $90.00 to $96.00 and gave the company a “buy” rating in a report on Monday, October 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $92.91.

DexCom Stock Performance

NASDAQ:DXCM opened at $82.29 on Monday. The company has a quick ratio of 1.40, a current ratio of 1.74 and a debt-to-equity ratio of 0.49. The business’s 50-day moving average price is $85.82 and its two-hundred day moving average price is $74.65. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The stock has a market cap of $30.69 billion, a P/E ratio of 32.27, a PEG ratio of 1.37 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.68 by $0.05. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The firm had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. During the same period last year, the firm posted $0.61 earnings per share. The business’s revenue was up 11.1% compared to the same quarter last year. As a group, equities analysts predict that DexCom, Inc. will post 2.67 EPS for the current fiscal year.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.